Drug Trial Radar · NCT06631287
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Nov 1, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Wes ElyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute on Aging (NIA)
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
Conditions
- Long COVID
- Sars-CoV-2 Infection
- Coronavirus Infections
- COVID-19
Interventions
BaricitinibDrug
4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
PlaceboOther
Matched placebo capsule, PO once daily for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CNS-Vital Signs Global Cognitive IndexTime frame: Month 6
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona · Recruiting
University of California, Los Angeles (UCLA)
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Colorado I Anschutz Medical Campus
Aurora, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Florida College of Medicine
Gainesville, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Illinois Research Network (ILLInet), University of Illinois Chicago
Chicago, Illinois · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
NYU Langone Health - Brooklyn
Brooklyn, New York · Recruiting
University Hospitals Cleveland Case Western
Cleveland, Ohio · Recruiting
The MetroHealth System
Cleveland, Ohio · Recruiting
Vanderbilt University Medical
Nashville, Tennessee · Recruiting
University of Texas at San Antonio
San Antonio, Texas · Recruiting
Swedish Medical Center
Seattle, Washington · Recruiting
West Virginia Clinical and Translational Science Institute
Morgantown, West Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.